BiopharmIQ also notes TRIUMPH-5, which pits retatrutide directly against tirzepatide, is still running. That sets the timeline for a possible approval filing.
Recap by typeshit. Post by BiopharmIQ by Amp on X.
A short Facebook share with no context on who used the peptides, where it happened or what followed.
Benzinga notes a 1.89% after-hours gain for Lilly stock, with Novo Nordisk also tagged. No further detail on what drove the move.
Mikhail Varshavski tells Fox News why protein matters, especially for GLP-1 users. He has a paid partnership with Quest Nutrition.
2:07:50
A live Q&A session covering GLP-1 drugs including Zepbound, Wegovy and Foundayo, with the host taking questions from viewers.
Amgen pointed to encouraging interim MariTide data and says the drug is moving quickly toward late-stage testing ahead of its Q3 earnings.
A short clip from the obesity doctor on eating while taking GLP-1 medications. Tap through for his take on food rules.
Loading…